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Purpose: The validity of tomotherapy-based simultaneous integrated boost (TOMO-
SIB) was assessed in terms of acute intestinal/urinary toxicity by comparing with 
3-dimensional conformal radiotherapy (3DCRT) in cases of whole-pelvis radiation 
therapy (WPRT) for prostate cancer. Materials and Methods: Thirty-eight consecu-
tive patients who underwent curative WPRT were retrospectively reviewed. Twenty 
six (68.4%) received 3DCRT and the others (31.6%) were treated with TOMOSIB. 
A local boost to the prostate circumferential area was added to WPRT sequentially 
for 3DCRT and concomitantly for TOMOSIB. The total median prostate or prostatic 
bed dose was 64.8 Gy including median 45.0 Gy of WPRT. Acute toxicities were as-
sessed according to RTOG criteria. Results: Overall intestinal toxicity was lower in 
TOMOSIB group than 3DCRT group (p=0.008). When it was divided into rectum 
and non-rectum intestine (NRI), TOMOSIB showed borderline superiority only in 
NRI toxicity (p=0.047). For the urinary toxicity, there was no significant difference 
between two groups (p=0.796). On dosimetric analysis for the rectum and bladder, 
dose delivered to 80% (p<0.001) and volume receiving 25‒40 Gy (p<0.001) were 
remarkably higher in 3DCRT. For the NRI, only maximum dose showed significant 
results between two groups (p<0.001). Conclusion: Intestinal toxicity should be ver-
ified with more detailed anatomic categorization such as rectum and NRI. TOMO-
SIB could not reduce urinary toxicity because of inevitably high dose exposure to the 
prostatic urethra. Current dosimetry system did not properly reflect intestinal/urinary 
toxicity, and suitable dosimetric guidelines are needed in TOMOSIB.
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INTRODUCTION
In the curative treatment of prostate cancer, whole-pelvis radiation therapy (WPRT) 
is prone to intestinal/urinary toxicities compared with prostate-only radiation. Al-
though acute intestinal/urinary toxicity has recently decreased in WPRT by using 
the intensity-modulation technique,1-4 the intestine, bladder, and other organs are 
still vulnerable to high-dose radiation because of their distensible properties.5 
There are also subtle differences in patient setup and dose delivery method accord-
ing to institutional protocol, which can aggravate these kinds of problems.
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tioned on the treatment couch using external markings. Dur-
ing simulation, patients lay supine with their hands on the 
anterior chest or arm holder. For TOMOSIB patients, body 
fixation devices such as Wing Board or Vac-Lok Cusion 
(CIVCO Medical Solutions, Kalona, IA, USA) were sup-
plemented. After scanning, CT datasets and structures were 
transferred to a planning workstation using Digital Imaging 
and Communications in Medicine system. In order to re-
produce this condition during daily radiotherapy, all pa-
tients were instructed to have their urinary bladder filled 
1‒2 hours before scanning. An air balloon of 60 mL vol-
ume was inserted into the rectum of TOMOSIB patients.
Clinical target volume and normal organ contouring
The clinical target volume (CTV) was classified as a three-
step (low-, intermediate-, and high-risk CTV) according to 
each irradiated dose level. Low-risk CTV was defined as 
pelvic lymph node area such as regional, internal iliac, ex-
ternal iliac, obturator, and distal common iliac lymph nodes. 
Presacral nodes were not routinely included. Seminal vesi-
cle and prostate circumference was assigned to intermedi-
ate- and high-risk CTV, respectively. For the patients who 
received radical prostatectomy previously, the location of 
surgical clips was used as a reference point to contour sur-
gical bed of prostate gland (high-risk CTV) or seminal ves-
icle (intermediate-risk CTV). They were contoured on each 
axial CT image with 0.5 to 1.0-cm radial expansion around 
each anatomic structure. The volume of bladder and rectum 
was also defined including their wall and inner space as a 
single structure, respectively. Rectum contouring was ex-
tended from the anus to the rectosigmoid flexure. Non-rec-
tum intestine (NRI) was delineated to encompass small bow-
el and colon from the upper margin of the rectum to the 
interspace between the 4‒5th lumbar spine.
3DCRT
A dose of 45 Gy was administered to low-risk CTV with 
4-field box technique. After 45 Gy, a dose of 9 Gy was add-
ed to intermediate-risk CTV followed by high-risk CTV 
dose of 16.2 Gy and 10.8 Gy for definitive and postopera-
tive irradiation, respectively. All local boosts to intermedi-
ate- and high-risk CTV were implemented with 5 to 7 por-
tals. The irradiated dose was adjusted according to each 
patient’s disease status. As a result, median irradiated dose 
was 64.8 Gy (range, 59.4‒75.6 Gy) to high-risk CTV and 
45.0 Gy (range, 41.4‒45.0 Gy) to low-risk CTV. The treat-
ment schedule was 5 fractions per week with a daily dose 
Tomotherapy delivers more uniform dose to the target 
volume and protects normal tissue through multi-leaf colli-
mators that can be used at any angle with 360-degree rota-
tion.6 Its mega-voltage computed tomography (MVCT) sys-
tem is used for correcting interfractional deviation which 
originated from internal organ motion or patient setup error. 
Daily MVCT imaging allows patients to be assessed for in-
terfractional changes of the intestine (especially rectum) or 
bladder in prostate cancer radiotherapy. Thus, high-dose ir-
radiation using simultaneous integrated boost (SIB) can be 
facilitated by tomotherapy. 
Hypofractionation with SIB can shorten the overall treat-
ment time and increase the local control rate. However, it 
also has limitations in avoiding acute toxicity problems even 
with intensity-modulated radiation therapy (IMRT) tech-
nique. As there is no definite guideline for fraction size and 
treatment duration, the validity of SIB remains to be dis-
cussed more in the era of IMRT. In this study, we intended to 
infer the usefulness of tomotherapy-based SIB (TOMOSIB) 
in terms of acute intestinal/urinary toxicity, by comparing it 
with 3-dimensional conformal radiotherapy (3DCRT), in 
cases of WPRT for prostate cancer. 
MATERIALS AND METHODS
This study was approved by the Institutional Review Board 
of our institution (approval number: YWMR-13-5-064).
Patient characteristics
Medical records and dosimetric data of 38 patients who re-
ceived WPRT between Jan 2007 and Dec 2012 were retro-
spectively reviewed. All pathologic diagnoses were adeno-
carcinoma, and median age was 68 years (range, 50‒79 
years). The aim of radiotherapy was definitive treatment for 
10 patients (26.3%) and salvage for the other 28 patients 
(73.7%). Hormonal agents were administered to 20 patients 
(52.6%) before radiation. Twelve patients (31.6%) were 
treated with TOMOSIB. Patient characteristics related to 
clinical factors are shown in Table 1. All patients had a per-
formance status of ECOG 0 or 1 and none had previous 
pelvic irradiation.
Patient setup and simulation
All patients were scanned with planning computed tomog-
raphy (CT) using a 3‒5 mm slice thickness including the 
pelvis and lower abdomen. The patients were initially posi-
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doses in definitive radiotherapy were 50.4 Gy, 60.2 Gy, and 
70.0 Gy for low-, intermediate-, and high-risk CTV, respec-
tively, with 28 fractions. Those of postoperative irradiation 
were 51.0 Gy, 54.0 Gy, and 66.0 Gy for low-, intermediate-, 
and high-risk CTV, respectively, with 30 fractions. Due to 
individual dose adjustment, actual median irradiated dose 
was 66.6 Gy (range, 66.0‒75.0 Gy) for high-risk CTV and 
51.0 Gy (range, 50.4‒54.0 Gy) for low-risk CTV. Dose to 
of 1.8 Gy. The Pinnacle system (ADAC Laboratories, Mil-
pitas, CA, USA) was used for treatment planning. Radia-
tion was delivered using a 10 to 15-MV photon beam and 
multi-leaf collimators with 0.7 to 1.0-cm expansion around 
each CTV.
TOMOSIB
TOMOSIB was planned by IMRT mode. The prescribed 
Table 1. Patient Characteristics
Feature Total TOMOSIB 3DCRT p value*
No. of patients 38 12 26
Age (yrs)   0.954†
    Mean 66.2±6.8 66.3±7.6 66.2±6.6
    Median 68 68 68
    Range 50‒79 50‒77 54‒79
Initial T stage (%)   0.170‡
    T1 1 (2.6)  1 (8.3) 0 (0.0)
    T2 16 (42.1)    3 (25.0) 13 (50.0)
    T3 16 (42.1)    7 (58.3)   9 (34.6)
    T4   5 (13.2)  1 (8.3)   4 (15.4)
Initial N stage (%) >0.999‡
    N0 37 (97.4) 12 (100) 25 (96.2)
    N1 1 (2.6)  0 (0.0) 1 (3.8)
Gleason score (%)   0.582‡
    2‒6 3 (7.9)  0 (0.0)   3 (11.5)
    7 15 (39.5)    6 (50.0)   9 (34.6)
    8‒10 20 (52.6)    6 (50.0) 14 (53.8)
Surgery type (%)   0.394‡
    Biopsy   9 (23.7)    5 (41.7)   4 (15.4)
    TURP 1 (2.6)  0 (0.0) 1 (3.8)
    Conventional RP 13 (34.2)    3 (25.0) 10 (38.5)
    Robot-assisted RP 15 (39.5)    4 (33.3) 11 (42.3)
Pretreatment hormone (%)   0.632§
    Yes 18 (47.4)    5 (41.7) 13 (50.0)
    No 20 (52.6)    7 (58.3) 13 (50.0)
Radiotherapy aim (%)   0.073‡
    Definitive 10 (26.3)    5 (41.7)   5 (19.2)
    Salvage (tumor recurrence) 1 (2.6)  1 (8.3) 0 (0.0)
    Salvage (biochemical relapse) 27 (71.1)    6 (50.0) 21 (80.8)
Prostate dose (Gy)   0.094†
    Mean 67.0±3.7 68.5±2.9 66.3±3.9
    Median 64.8 66.6 64.8
    Range 59.4‒75.6 66.6‒75.0 59.4‒75.6
Whole pelvis dose (Gy) <0.001†
    Mean 46.9±3.2 51.4±1.3 44.9±3.9
    Median 45.0 51.0 45.0
    Range 41.4‒54.0 50.4‒54.0 41.4‒45.0
TURP, transurethral resection of prostate; RP, radical prostatectomy; 3DCRT, 3-dimensional conformal radiotherapy; TOMOSIB, tomotherapy-based simul-
taneous integrated boost.
*Statistical analysis between TOMOSIB and 3DCRT.
†Student t-test.
‡Fisher exact test.
§Chi-square test.
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was used for dosimetric comparison of each normal organ 
between TOMOSIB and 3DCRT. Statistical significance was 
defined at the p<0.05 level. The SPSS (Version 20.0, SPSS 
Inc., Chicago, IL, USA) program was used for analysis.
RESULTS
 
Most treatment processes were tolerable, and none of the 
38 patients experienced interruption due to radiation-in-
duced toxicity. Only one 54-year-old patient, who received 
3DCRT, suffered from underlying internal hemorrhoid and 
anal fissure. This patient received conservative surgical care 
after 45 Gy.
Acute intestinal toxicity
Twenty-five patients (65.8%) experienced acute intestinal 
toxicity and 15 patients (39.5%) suffered from Grade 2 tox-
icity. No Grade 3‒5 toxicity was observed. Among 15 pa-
tients who had Grade 2 intestinal toxicity, 7 exhibited defe-
cation-related symptoms such as diarrhea or tenesmus, 3 
showed severe anal pain requiring analgesics, and 4 com-
plained of rectal bleeding. One patient suffered from both 
frequent defecation and rectal bleeding.
The proportion of Grade 2 or higher intestinal toxicity 
was relatively lower in TOMOSIB group than in 3DCRT 
rectum, bladder, NRI, and femoral heads was constrained 
by mean dose of 27 Gy, 25 Gy, 25 Gy, and 30 Gy, respec-
tively. The treatment schedule was 5 fractions per week with 
a daily dose of 2.2‒2.5 Gy for high-risk CTV. Inverse treat-
ment planning, which is based on iterative least squares mini-
mization of an objective function, as described by Shepard, 
et al.,7 was applied using TomoTherapy Hi-Art System ver-
sion 2.0 (TomoTherapy Incorporated, Madison, WI, USA). 
Daily MVCT was scanned prior to each treatment session 
for the image-guided verification.
Acute toxicity assessment
During radiotherapy, acute intestinal/urinary toxicity was 
estimated on a weekly basis according to RTOG scoring 
system.8 Toxicity assessment was dependent mainly on pa-
tients’ subjective complaints, and the maximum toxicity in-
cidence was compared between TOMOSIB and 3DCRT. 
We focused on the incidence, not on the duration or recur-
rence of each symptom, in order to exclude the influence of 
medicines used for symptom palliation. Pretreatment symp-
toms were also excluded to reflect radiation toxicity as pure-
ly as possible. 
Statistical analysis
Correlations between clinical factors and acute intestinal/uri-
nary toxicity were evaluated by chi-square test. Student t-test 
Table 2. Univariate Analysis for Acute Intestinal/Urinary Toxicity of Grade 2 or Higher
Intestinal toxicity of Grade 2 or higher Urinary toxicity of Grade 2 or higher
Proportion of patients (%) p value Proportion of patients (%) p value
Age at at diagnosis (yrs) 0.927 0.212
    <70 10/25 (40.0) 12/25 (48.0)
    ≥70   5/13 (38.5)   9/13 (69.2)
Radical prostatectomy 0.588 0.153
    Yes 11/28 (39.3) 13/28 (46.4)
    No   4/10 (40.0)   8/10 (80.0)
ADT before radiotherapy 0.157 0.012
    Yes   9/18 (50.0) 14/18 (77.8)
    No   6/20 (30.0)   7/20 (35.0)
Urinary symptom at diagnosis 0.697
    Yes N/A 16/28 (57.1)
    No N/A   5/10 (50.0)
Radiation technique 0.008 0.796
    TOMOSIB 1/12 (8.3)   7/12 (58.3)
    3DCRT 14/26 (53.8) 14/26 (53.8)
Treatment aim 0.588 0.153
    Definitive   4/10 (40.0)   8/10 (80.0)
    Postoperative 11/28 (39.3) 13/28 (46.4)
ADT, androgen deprivation therapy; N/A, not applicable; 3DCRT, 3-dimensional conformal radiotherapy; TOMOSIB, tomotherapy-based simultaneous inte-
grated boost.
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almost the same (around 45 Gy), the cumulative incidence 
of Grade 2 or higher toxicity was 0.0% (0 patient) in TOMO-
SIB group and 30.8% (8 patients) in 3DCRT group (Fig. 1). 
More specifically, it was 11.5% (3 patients) for the rectum 
and 19.2% (5 patients) for the NRI in 3DCRT group (Fig. 2).
Acute urinary toxicity
Thirty-three patients (86.8%) revealed acute urinary toxici-
ty and 21 patients (55.3%) suffered from Grade 2 or higher 
toxicity including 1 patient (2.6%) of Grade 3 toxicity. No 
Grade 4‒5 toxicity was observed. Among 21 patients 
(55.3%) who had Grade 2 or higher toxicity, 18 experi-
enced frequency-related symptoms and the others showed 
painful voiding.
The ratio of Grade 2 or higher toxicity did not differ signif-
icantly between TOMOSIB and 3DCRT groups (p=0.796) 
(Table 2). Age, radical prostatectomy, and pretreatment 
symptom were not associated with Grade 2 or higher toxic-
ity. Postoperative irradiation also was not different from de-
finitive radiotherapy in the ratio of higher urinary toxicity 
(p=0.153). Only ADT seemed to be associated (p=0.012). 
Fourteen (77.8%) out of 18 patients, who were treated with 
ADT, revealed severe toxicity. All toxicities of Grade 2 or 
higher appeared between the 2nd and 8th week during ra-
diotherapy (Fig. 3). At the 5th week of radiotherapy, the cu-
mulative incidence of Grade 2 or higher toxicity was 41.7% 
(5 patients) in TOMOSIB group and 26.9% (7 patients) in 
3DCRT group.
group (p=0.008) (Table 2). When intestinal toxicity was an-
alyzed separately for rectum and NRI, there was no signifi-
cant difference in acute rectal toxicity between two groups 
(p=0.191) (Table 3). TOMOSIB displayed borderline supe-
riority only in NRI toxicity (p=0.047). Other clinical factors, 
such as age, radical prostatectomy, androgen deprivation 
therapy (ADT), and pretreatment urinary symptom, were 
not associated with Grade 2 or higher intestinal toxicity. 
Postoperative irradiation was not different from definitive 
radiotherapy for intestine, rectum, and NRI toxicity. All tox-
icities of Grade 2 or higher appeared between the 3rd and 
the 7th week during radiotherapy. At the 5th week of radio-
therapy, when the WPRT dose levels of both groups were 
Table 3. Univariate Analysis for Acute Rectal/NRI Toxicity of Grade 2 or Higher
Rectum NRI
Proportion of patients (%) p value Proportion of patients (%) p value
Age at diagnosis (yrs) 0.537 0.593
    <70   6/25 (24.0)   4/25 (16.0)
    ≥70   2/13 (15.4)   3/13 (23.1)
Radical surgery 0.453 0.143
    Yes   7/28 (25.0)   4/28 (14.3)
    No   1/10 (10.0)   3/10 (30.0)
ADT before radiotherapy 0.795 0.133
    Yes   4/18 (22.2)   5/18 (27.8)
    No   4/20 (20.0)   2/20 (10.0)
Radiation technique 0.191 0.047
    TOMOSIB 1/12 (8.3) 0/12 (0.0)
    3DCRT   7/26 (26.9)   7/26 (26.9)
Treatment aim 0.453 0.143
    Definitive   1/10 (10.0)   3/10 (30.0)
    Postoperative   7/28 (25.0)   4/28 (14.3)
NRI, non-rectum intestine; ADT, androgen deprivation therapy; 3DCRT, 3-dimensional conformal radiotherapy; TOMOSIB, tomotherapy-based simultane-
ous integrated boost.
Fig. 1. The cumulative incidence of the Grade 2 or higher intestinal toxicity 
from the 1st to the 8th week during radiotherapy (TOMOSIB vs. 3DCRT).
TOMOSIB, tomotherapy-based simultaneous integrated boost; 3DCRT, 3-di-
mensional conformal radiotherapy.
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should be reassessed and more careful approaches are need-
ed in terms of radiation toxicity.
WPRT is recommended for the treatment of locally ad-
vanced prostate cancer considering high probability of lymph 
node metastasis.9-11 Roach, et al.12,13 suggested a formula to 
predict the risk of lymph node involvement in clinically lo-
calized prostate cancer using prostate-specific antigen and 
Gleason score. In the RTOG 9413 trial, patients treated 
with WPRT experienced a 4-year progression-free survival 
of 54.2% compared to 47.0% in those with prostate-only 
radiation (p=0.020), when 1323 patients with an estimated 
risk of lymph node involvement of 15% were randomized 
to both groups.9 However, WPRT generally leads to more 
severe intestinal/urinary toxicity than prostate-only radio-
therapy. This problem cannot be solved even with IMRT 
technique. Deville, et al.14 reported that whole-pelvis IMRT 
increased acute gastrointestinal toxicity in comparison with 
prostate-only IMRT. In addition, SIB can aggravate this 
Dosimetric comparison
In all TOMOSIB plans, dose distributions for each CTV 
and normal organ were generally acceptable. However, the 
dose homogeneity for CTV was limited compared with that 
of 3DCRT plan (Fig. 4). When dosimetric assessment was 
confined to the dose level at the time of full irradiation for 
the pelvic lymph node area, most parameters for normal or-
gans were better in TOMOSIB than in 3DCRT. For the rec-
tum, the mean dose, dose delivered to 80% volume, and the 
volume receiving 15‒45 Gy were lower in TOMOSIB than 
in 3DCRT. For the bladder, dose delivered to 80% volume 
and the volume receiving 25‒45 Gy were lower in TOMO-
SIB than in 3DCRT. For the NRI, overall dosimetric data 
did not show significant difference between TOMOSIB and 
3DCRT, except maximum dose. The dose-volume histo-
gram (DVH) data for concerned normal organs are shown in 
Table 4. In terms of treatment aim, dose-volume relationship 
between definitive and postoperative irradiation was not def-
initely different for the rectum, bladder, and NRI (Table 5). 
DISCUSSION
The main objective of this study was to compare the acute 
intestinal/urinary toxicities of TOMOSIB with those of 
3DCRT during WPRT. Generally, TOMOSIB was more ef-
fective than 3DCRT in alleviating acute intestinal toxicity. 
However, this was not obvious when the intestine was di-
vided into rectum and NRI. Acute urinary toxicity was not 
reduced by TOMOSIB despite better bladder dose distribu-
tion. Dosimetric values for rectum and bladder were not cor-
related with acute intestinal/urinary toxicities. These data 
suggest that current dosimetric analysis for TOMOSIB 
Fig. 3. The cumulative incidence of the Grade 2 or higher urinary toxicity 
from the 1st to the 8th week during radiotherapy (TOMOSIB vs. 3DCRT). 
TOMOSIB, tomotherapy-based simultaneous integrated boost; 3DCRT, 3-di-
mensional conformal radiotherapy.
Fig. 2. The cumulative incidence of the Grade 2 or higher toxicity for the rectum (A) and the NRI (B) from the 1st to the 8th week during radiotherapy (TOMOSIB 
vs. 3DCRT). NRI, non-rectum intestine; TOMOSIB, tomotherapy-based simultaneous integrated boost; 3DCRT, 3-dimensional conformal radiotherapy.
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ever, TOMOSIB still seemed to be satisfactory for the rec-
tal toxicity despite relatively high dose exposure. This could 
be confirmed by relatively few cases of Grade 2 or higher 
toxicity and better dosimetric results (Table 4).
The effect of tomotherapy itself needs to be ascertained 
with that of rectal ballooning. Correlations between rectal 
dose exposure and gastrointestinal toxicity were reported in 
problem. Thus, current SIB technique needs to be investi-
gated. We analyzed TOMOSIB in terms of acute intestinal/
urinary toxicity by comparing it with 3DCRT.
For acute intestinal toxicity, TOMOSIB exhibited rela-
tively good results despite its higher dose level than that of 
3DCRT. When the NRI was analyzed separately from intes-
tine, the toxicity gap between two groups decreased. How-
Table 4. Dosimetric Comparison for Rectum, Bladder, and NRI between TOMOSIB and 3DCRT When All Prescription Doses 
Were Irradiated to the Pelvic Lymph Node Area for Both Groups
Rectum Bladder NRI
TOMOSIB* 3DCRT† p value TOMOSIB* 3DCRT† p value TOMOSIB* 3DCRT† p value
Maximum dose (Gy) 52.3±8.8 45.8±0.6 0.026   52.4±10.6   46.4±0.5   0.076 53.4±3.2 46.8±0.6 <0.001
Mean dose (Gy) 24.9±4.2 39.6±3.4 <0.001 26.7±4.3   43.3±2.3 <0.001 11.1±5.6 11.2±4.5 0.975
D80 (Gy) 19.1±3.7 34.8±6.7 <0.001 20.8±3.3   40.0±6.0 <0.001   1.1±0.7   1.1±0.8 0.983
V15 (%) 88.1±7.9 98.6±1.6 0.001 97.8±3.9 100.0±0.0   0.078   33.8±12.8   30.2±12.8 0.471
V25 (%)   48.3±21.0 95.2±5.7 <0.001   49.1±25.1   99.0±2.5 <0.001   20.8±10.7 20.8±9.0 0.990
V40 (%)   5.5±7.6   68.4±18.4 <0.001   5.5±8.0     87.0±14.0 <0.001   4.5±5.0   7.8±5.5 0.108
V45 (%)   3.0±5.3   20.2±24.8 0.029   3.1±6.1     57.8±24.3 <0.001   1.9±3.2   3.5±3.3 0.216
D80, dose delivered to 80% volume; Vn, volume percentage above nGy; NRI, non-rectum intestine; 3DCRT, 3-dimensional conformal radiotherapy; TOMO-
SIB, tomotherapy-based simultaneous integrated boost.
*For TOMOSIB, whole pelvic dose ranged from 50.4–54.0 Gy with simultaneous integrated boost to prostatic circumference.
†For 3DCRT, whole pelvic dose ranged from 41.4–45.0 Gy.
Table 5. Dosimetric Comparison for Rectum, Bladder, and NRI between Definitive and Postoperative Radiotherapy When All 
Prescription Doses Were Irradiated to the Pelvic Lymph Node Area for Both Groups
Rectum Bladder NRI
Definitive Postoperative p value Definitive Postoperative p value Definitive Postoperative p value
Maximum dose (Gy) 53.2±9.6 47.2±4.6 0.046 53.8±9.8 47.5±6.3 0.070 49.7± 3.7 51.5±5.3 0.330
Mean dose (Gy) 30.8±9.2 33.3±8.3 0.510 33.2±8.7 36.2±9.3 0.470 10.6±4.9 13.1±5.3 0.284
D80 (Gy)   26.6±11.9 27.5±9.0 0.852   28.4±11.6   31.7±10.8 0.516   1.2±0.6   1.0±1.1 0.395
V15 (%) 94.3±8.1 93.3±7.7 0.780 97.3±5.1 99.6±0.9 0.657   29.6±11.2   40.6±15.2 0.059
V25 (%)   62.6±28.4   76.6±27.9 0.272   69.4±27.5   77.2±32.3 0.579 19.0±8.4   27.3±12.0 0.062
V40 (%)   31.9±41.4   40.7±33.1 0.586   33.1±44.6   53.7±42.4 0.295   5.4±5.2   8.8±6.1 0.185
V45 (%)   7.5±8.0   13.7±22.9 0.493   23.6±35.2   34.6±32.6 0.467   2.3±3.1   4.1±4.0 0.216
D80, dose delivered to 80% volume; Vn, volume percentage above nGy; NRI, non-rectum intestine.
Fig. 4. A typical example of dose-volume histogram at completion of whole-pelvis radiation for (A) TOMOSIB and (B) 3DCRT. CTV, clinical target volume; 
3DCRT, 3-dimensional conformal radiotherapy; TOMOSIB, tomotherapy-based simultaneous integrated boost.
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radiotherapy, because positional change of each normal or-
gan after surgical resection can increase the possibility of 
overlapping with CTV dose area. In our study, however, the 
postoperative irradiation did not show significant toxicity 
difference from definitive radiotherapy for the rectum, blad-
der, and NRI. Dose-volume relationship was almost the 
same pattern as clinical outcome. Only in the low-dose sec-
tion of NRI DVH, the volume of postoperative irradiation 
had a tendency to be relatively large (Table 5). Therefore, 
surgical influence can be considered slight in overall dose 
distribution and toxicity.
There have been some earlier reports about the negative 
influence of hormone therapy upon urinary toxicity in pa-
tients treated with radiotherapy, although the mechanism 
remains unclear.24-26 In our study, ADT seemed to be related 
to Grade 2 or higher urinary toxicity, but this cannot be re-
garded as the influence of ADT itself because of the small 
number of cases and diverse kinds of hormonal agents. The 
toxicity increase by ADT should be evaluated in more de-
tail by homogeneous hormonal agents in future studies. 
Ideally, late toxicity with long-term follow-up is the ulti-
mate endpoint to be evaluated. However, only acute toxicity 
was analyzed in this study for the following reasons. First, 
acute toxicity can be an index for predicting the late toxici-
ty.24,27,28 Second, late toxicity assessment is limited due to pal-
liated symptoms after conservative care or medication while 
acute toxicity is relatively free from this point. In addition, 
acute toxicity usually progresses to late toxicity in the same 
way for both gastrointestinal and genitourinary symptoms.28
This study has a limitation stemming from its small num-
ber of patients, apart from the heterogeneity of treatment 
such as definitive radiotherapy versus postoperative irradia-
tion. These points should be improved with more systemat-
ic approach in future studies.
Taken together, acceptable acute intestinal toxicity results 
by TOMOSIB should be verified with more detailed ana-
tomic categorization such as rectum and NRI. In estimating 
urinary toxicity, bladder dosimetry has some limitations, and 
prostatic urethra must be concerned. Consequently, more 
deliberate approach with proper dosimetric guidelines is 
suggested in TOMOSIB, especially for WPRT.
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previous studies along with the usefulness of balloon inser-
tion.15-20 According to Storey, et al.,15 rectal volume over 70 
Gy is significantly related to its toxicity. Michalski, et al.17 
showed that acute bowel symptoms are associated with the 
percentage of the rectum receiving a reference dose or great-
er through multivariate analysis of 219 patients (p=0.012). 
This kind of ballooning effect has also been mentioned by 
Cho, et al.18 for the SIB treatment planned with IMRT meth-
od, where the toxicity reduction was not as remarkable as 
for 3DCRT. In our study, all TOMOSIB patients were treat-
ed with balloon inserted. Therefore, low incidence of Grade 
2 or higher intestinal toxicity in TOMOSIB cannot always 
be considered as the influence of tomotherapy itself.
The intestinal/urinary toxicity results were not always 
consistent with its dosimetric values. For example, the NRI 
dosimetry data were not significantly different between 
TOMOSIB and 3DCRT, except maximum dose, despite its 
toxicity difference. One of the reasons may be non-stan-
dardized contouring system for NRI. For urinary system, 
the disagreement pattern between toxicity and dosimetry 
was the same as for the NRI. This was the same in other 
IMRT studies for urinary toxicity.21-23 One possible reason 
is the high dose exposure to the bladder area which was 
overlapped directly with high-risk CTV. Subjective bladder 
filling can be another factor for high dose exposure because 
of its irregular distension. 
Most of all, hypofractionated schedule of TOMOSIB with 
higher dose level could lead to unsatisfactory outcome in 
urinary toxicity, which can be estimated in terms of urethral 
and prostate doses. According to Keiler, et al.,21 tomothera-
py could not provide satisfactory genitourinary toxicity re-
sults in the post-prostatectomy subset because of inevitable 
high dose exposure to urethral and prostate areas. Di Muzio, 
et al.1 reported the excellent genitourinary toxicity results in 
a phase I‒II study on hypofractionated TOMOSIB. Howev-
er, this may not be compared with our study because only 
half of the 60 patients received WPRT. In our study, TO-
MOSIB showed higher maximum toxicity incidence from 
the 1st to the 5th week during radiotherapy even though 
most bladder dosimetric parameters were lower than those 
of 3DCRT, except the maximum dose. According to DVHs 
of TOMOSIB, the prostatic circumferential area showed 
relatively poor dose homogeneity, which means much more 
irradiation to the prostatic urethra than initially planned 
dose (Fig. 4). 
Usually, postoperative irradiation appears to be more vul-
nerable in terms of intestinal/urinary toxicity than definitive 
Sei Hwan You, et al.
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